Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| NewAmsterdam Pharma Co N.V. | 11,321,366 | reported | 11 Dec 2024 | tx 5−462,288 |
| enGene Holdings Inc. | 3,032,430 | reported | 30 Oct 2024 | tx 1+561,797 |
| Forbion European Acquisition Corp. | 1,373,496 | reported | 27 Oct 2023 | tx 3+2,373,496−1,373,496 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 10 Dec 2024 | SALE | NewAmsterdam Pharma Co N.V. | 48,511 | 26.15 USD | |
| 11 Dec 2024 | SALE | NewAmsterdam Pharma Co N.V. | 130,561 | 25.26 USD | |
| 11 Dec 2024 | SALE | NewAmsterdam Pharma Co N.V. | 18,583 | 26.41 USD | |
| 11 Dec 2024 | SALE | NewAmsterdam Pharma Co N.V. | 4,894 | 27.11 USD | |
| 10 Dec 2024 | SALE | NewAmsterdam Pharma Co N.V. | 259,739 | 25.22 USD | |
| 30 Oct 2024 | PURCHASE | enGene Holdings Inc. | 561,797 | 8.90 USD | |
| 27 Oct 2023 | CONVERSION | Forbion European Acquisition Corp. | 1,373,496 | — | |
| 27 Oct 2023 | CONVERSION | Forbion European Acquisition Corp. | 1,373,496 | — | deriv |
| 27 Oct 2023 | GRANT_AWARD | Forbion European Acquisition Corp. | 1,000,000 | 1.50 USD | deriv |